Diaprost announced today that it has signed an exclusive license agreement with Memorial Sloan Kettering Cancer Center for IP related to the use of PSA antibodies for therapeutic and diagnostic purposes for prostate cancer.
Press release Diaprost August 25
Pressmeddelande Diaprost 25 augusti